Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
PULSE BIOSCIENCES, INC. (PLSE) reported that Jon Skinner, the company’s Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The filing does not report any specific share holdings or transactions and notes an attached Exhibit 24 Power of Attorney.
Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, under which the company may, from time to time, offer and sell shares of its common stock having an aggregate offering price of up to $75,000,000.
Sales may be made as “at the market” offerings under Rule 415 through ordinary brokers’ transactions on The Nasdaq Capital Market, to or through market makers, block trades, or other permitted negotiated methods, at market, related, or negotiated prices. The company will pay Mizuho a commission of up to 3.0% of the gross sales price of shares sold, reimburse specified expenses, is not obligated to sell any shares, and may suspend solicitations. The shares are registered on Form S-3 (File No. 333-293596), declared effective February 27, 2026, with a prospectus supplement filed August 6, 2026.
Pulse Biosciences, Inc. is establishing an at-the-market equity program to sell up to $75,000,000 of common stock from time to time through Mizuho Securities USA LLC under an existing $200,000,000 shelf registration. Mizuho will act as sales agent on commercially reasonable efforts terms and receive up to 3% of gross proceeds as commissions.
The company had 70,799,962 shares outstanding as of June 30, 2026; an illustrative sale of 1,978,891 shares at $37.90 per share would raise approximately $75 million and increase shares outstanding to 72,778,853. Historical net tangible book value was $96.5 million, or $1.36 per share, and would rise to $169.0 million, or $2.32 per share on an illustrative basis, implying dilution of $35.58 per share at a $37.90 offering price.
Net proceeds are intended for general corporate purposes, including clinical evaluations and IDE studies for the nPulse Cardiac Catheter and nPulse Cardiac Clamp in the United States and Europe, regulatory submissions, and further development and commercialization of the Vybrance Percutaneous Electrode System and other NPS-based products.
Pulse Biosciences, Inc., a novel ablation company developing Nano-pulse Stimulation and nsPFA technology for atrial fibrillation and soft-tissue applications, reported Q2 2026 product revenue of $434 thousand and a net loss of $24.7 million, or $0.36 per share.
For the first half of 2026, the company generated $835 thousand of product revenue and recorded a net loss of $43.2 million, driven mainly by $29.6 million in research and development and $15.0 million in selling, general and administrative expenses, including $6.9 million of stock-based compensation.
Cash and cash equivalents were $101.6 million at June 30, 2026, and management believes existing resources are sufficient for at least one year. During the quarter Pulse Biosciences raised $46.8 million of net proceeds by issuing 1.92 million shares through an at-the-market program, including purchases by its majority stockholder and CEO, and continued pivotal trials of its nPulse cardiac catheter and surgical clamp systems and market development of the Vybrance Percutaneous Electrode System.
Pulse Biosciences, Inc. reported second quarter 2026 results and clinical updates. Total revenue for the three months ended June 30, 2026 was $0.4 million from product sales during a controlled commercial launch focused on market development and increased procedural utilization. GAAP costs and expenses were $25.7 million, and GAAP net loss was $24.7 million; non-GAAP costs and expenses were $20.5 million with non-GAAP net loss of $19.4 million, primarily reflecting higher clinical program and compensation spending.
The company highlighted rapid, efficient procedures in its endocardial catheter atrial fibrillation program and continued progress toward a CE Mark submission in the second half of 2026, with potential approval anticipated by the middle of 2027. Enrollment in the U.S. pivotal NANOPULSE-AF study has passed the halfway point, even after a 19-patient increase in the enrollment target, and completion is still anticipated by early Q4 2026. Pulse Biosciences announced a partnership with the Clayman Thyroid Center to evaluate its Vybrance system for benign thyroid nodules. Cash and cash equivalents totaled $101.6 million as of June 30, 2026, after raising $46.8 million in net proceeds under an at-the-market program during the quarter and an additional $10.7 million afterward, and the company established a new $75 million ATM facility alongside an effective shelf registration for up to $125 million.
Pulse Biosciences announced that the NANOPULSE-AF pivotal IDE clinical study of its nPulse Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation has surpassed its enrollment midpoint. The prospective, multicenter investigation began in April 2026 and is expected to enroll patients at up to 30 sites, including locations outside the United States.
The company’s nano-PFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue and initiating regulated cell death. Management plans to provide additional commentary on study progress during an earnings conference call on August 6 at 1:30pm PT / 4:30pm ET, available via phone and webcast.
PULSE BIOSCIENCES, INC. director Mahkam Zanganeh reported receiving two stock option grants. The options cover 14,504 and 30,000 shares of common stock at an exercise price of $26.89 per share and expire on June 11, 2036.
The 14,504-share option vests in equal monthly installments over one year starting on July 11, 2026, subject to continued service. The 30,000-share option vests in equal quarterly installments over one year starting on September 5, 2026. These are compensation-related awards, not open-market share purchases or sales.
PULSE BIOSCIENCES, INC. director Richard van den Broek reported receiving two stock option grants. Each option is a right to buy Common Stock at an exercise price of $26.89 per share and expires on June 11, 2036.
One option covering 8,423 shares vests in equal monthly installments over one year starting on July 11, 2026, subject to his continued service. The other option covering 30,000 shares vests in equal quarterly installments over one year starting on September 5, 2026, also contingent on continued service. These are compensation-related awards, not open-market purchases or sales.
PULSE BIOSCIENCES, INC. director and 10% owner Robert W. Duggan received two stock option grants as equity compensation. He was awarded options for 12,495 shares and 30,000 shares of common stock at an exercise price of $26.89 per share, expiring on June 11, 2036. The options vest over one year, with one grant vesting in equal monthly installments starting on July 11, 2026 and the other vesting in equal quarterly installments starting on September 5, 2026, subject to his continued service.
Pulse Biosciences director Manmeet Singh Soni received a grant of stock options, not a share purchase. The award covers 30,000 options to buy Common Stock at an exercise price of $26.89 per share, expiring on June 11, 2036. These options vest in equal monthly installments over one year, starting on July 11, 2026, contingent on continued service, leaving Soni with 30,000 derivative securities after the grant.